Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
ImmunogenX logo — Advancing celiac disease management with Latiglutenase thera...

ImmunogenX

Advancing celiac disease management with Latiglutenase therapy, innovative diagnostic tools, and pioneering gluten detection methods.

Founded 2013 Grant Biotechnology, Health Care

General Information

Company Name ImmunogenX
Founded Year 2013
Founders / Decision Makers
Team member
Industries Biotechnology, Health Care
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with ImmunogenX. To contact ImmunogenX, visit immunogenx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ImmunogenX compare?

A PDF of ImmunogenX and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ImmunogenX soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ImmunogenX

ImmunogenX® is a clinical-stage biotherapeutics company established in 2013, dedicated to advancing celiac disease management. Their flagship product, Latiglutenase, shows promise in revolutionizing the treatment of celiac disease. Supported by leading experts in celiac disease research, ImmunogenX is also developing CypCel™, a minimally-invasive diagnostic tool to monitor celiac disease management. This innovative tool will utilize a clinically meaningful metabolic marker to assess the recovery status of patients undergoing gluten-free diets or other treatments. In addition to therapeutics and diagnostics, ImmunogenX is working on enhancing food safety by employing advanced mass spectrometry techniques to detect and quantify critical gluten peptide sequences found in wheat, barley, and rye. The most recent investment in ImmunogenX was a grant investment received on 11 April 2019 from the National Institute of Allergy and Infectious Diseases. As a company operating within the Biotechnology and Health Care industries, ImmunogenX is positioned at the forefront of advancing celiac disease treatment and diagnosis. Their commitment to innovation in therapy, diagnostics, and food safety for celiac patients makes them a noteworthy player in the biotech landscape.

Business keywords: Celiac disease, Latiglutenase therapy, Biotherapeutics, Diagnostic tools, Gluten detection, ImmunogenX, Clinical-stage, Mass spectrometry, Food safety

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Grant Undisclosed 1
National Institute of Allergy and Infectious Diseases
11 Apr 2019

ImmunogenX Alternatives & Competitors

View All Alternatives
ImmunogenX vs
Entero Therapeutics (Nasdaq: ENTO)
Entero Therapeutics (Nasdaq: ENTO) United States

A biopharma company focused on the development of targeted, non-systemic therapies for gastrointesti...

Post-IPO Equity
12 employees
Biotechnology, Health Care
ImmunogenX vs
ImmusanT
ImmusanT

Pioneering advancements for celiac disease through innovative diagnostics and therapeutic solutions

Venture round
Biotechnology, Health Care
ImmunogenX vs
Biodesix, Inc.
Biodesix, Inc. United States

Leading Diagnostic Solutions Company | Nasdaq: BDSX | 2026 & 2025 & 2024 Top Workplaces Award Winner

Post-IPO Equity
356 employees
Biotechnology, Health Care
View all alternatives

FAQ About ImmunogenX

Advancing celiac disease management with Latiglutenase therapy, innovative diagnostic tools, and pioneering gluten detection methods.
ImmunogenX was founded in 2013.
ImmunogenX operates in Biotechnology and Health Care. Its work centres on Celiac disease, Latiglutenase therapy, Biotherapeutics and Diagnostic tools.
ImmunogenX has completed 1 funding round. The latest funding stage is Grant.
Top alternatives and competitors to ImmunogenX include Entero Therapeutics (Nasdaq: ENTO), ImmusanT, Biodesix, Inc., LinXis Biopharmaceuticals, Corrixr Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ImmunogenX and Entero Therapeutics (Nasdaq: ENTO) are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ImmunogenX, https://bouncewatch.com/company/immunogenx, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes